Pfizer Inc. (NYSE:PFE) Shares Sold by Signet Financial Management LLC

Signet Financial Management LLC lessened its holdings in Pfizer Inc. (NYSE:PFE) by 71.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,702 shares of the biopharmaceutical company’s stock after selling 29,889 shares during the quarter. Signet Financial Management LLC’s holdings in Pfizer were worth $325,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Advisor OS LLC grew its stake in shares of Pfizer by 1.0% during the 4th quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock worth $1,013,000 after purchasing an additional 365 shares during the period. Safeguard Investment Advisory Group LLC lifted its holdings in Pfizer by 3.9% in the 4th quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock valued at $288,000 after purchasing an additional 371 shares in the last quarter. Lantz Financial LLC lifted its holdings in Pfizer by 1.3% in the 1st quarter. Lantz Financial LLC now owns 30,582 shares of the biopharmaceutical company’s stock valued at $849,000 after purchasing an additional 381 shares in the last quarter. King Wealth Management Group lifted its holdings in Pfizer by 2.4% in the 4th quarter. King Wealth Management Group now owns 16,686 shares of the biopharmaceutical company’s stock valued at $480,000 after purchasing an additional 388 shares in the last quarter. Finally, Advance Capital Management Inc. raised its holdings in shares of Pfizer by 4.0% during the 4th quarter. Advance Capital Management Inc. now owns 10,177 shares of the biopharmaceutical company’s stock worth $293,000 after acquiring an additional 391 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on PFE shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Wednesday. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Morgan Stanley lifted their price target on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. Finally, BMO Capital Markets reissued an “outperform” rating and set a $36.00 price objective (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Ten analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $35.86.

Pfizer Stock Up 0.4 %

Shares of PFE traded up $0.12 during midday trading on Thursday, hitting $27.54. The company had a trading volume of 13,344,681 shares, compared to its average volume of 40,849,289. The company’s 50-day simple moving average is $27.81 and its 200-day simple moving average is $27.69. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. The firm has a market capitalization of $156.06 billion, a P/E ratio of -458.26, a P/E/G ratio of 1.10 and a beta of 0.70. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $37.80.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.26. The business had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The business’s quarterly revenue was down 19.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.23 EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 6.10%. Pfizer’s payout ratio is -2,799.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.